You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

 

Online download statistics by month:

Online download statistics by month: June 2022 to July 2025

AbstractFullPdf
Jun 2022521535215
Jul 2022613620170
Aug 20221311131683
Sep 202229129274
Oct 202223924463
Nov 202221721767
Dec 202216016245
Jan 202316616743
Feb 202312012249
Mar 202311411646
Apr 202313413430
May 202310710840
Jun 202318518524
Jul 202310710736
Aug 2023858538
Sep 2023717222
Oct 2023818531
Nov 202311911932
Dec 2023848731
Jan 2024868741
Feb 2024838336
Mar 2024979855
Apr 202411411540
May 2024959527
Jun 2024888836
Jul 202412112342
Aug 2024787733
Sep 202498972703
Oct 2024929324
Nov 2024798027
Dec 2024828429
Jan 2025929432
Feb 202511911945
Mar 2025959558
Apr 202511311359
May 2025575859
Jun 2025565639
Jul 2025110
Total637164294524